N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: Relevance to schizophrenia and bipolar disorder

Neuroscience Letters

Volumn 499, Issue 3, 2011, Pages 149-153

  Dean, Olivia M ^a,b,c   Van Den Buuse, Maarten ^a,b   Berk, Michael ^a,b,c   Copolov, David L ^a,d   Mavros, Christine ^a,d   Bush, Ashley I ^a,b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

2 Cyclohexene 1 one (CHX); Acetyl cysteine; Amphetamine; Bipolar disorder; Glutathione; Schizophrenia

Indexed keywords

2 CYCLOHEXENONE; ACETYLCYSTEINE; AMPHETAMINE; DEXAMPHETAMINE; GLUTATHIONE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; FRONTAL CORTEX; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEPLETION; RAT; SCHIZOPHRENIA;

ACETYLCYSTEINE; ANIMALS; BIPOLAR DISORDER; BRAIN; CORPUS STRIATUM; CYCLOHEXANONES; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; FRONTAL LOBE; GLUTATHIONE; MALE; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA;

EID: 79960084100     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.05.027     Document Type: Article

References (48)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., van Dyck C.H., Charney D.S., Innis R.B., Laruelle M. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry 1998, 155:761-767.
2. Achat-Mendes C., Anderson K.L., Itzhak Y. Impairment in consolidation of learned place preference following dopaminergic neurotoxicity in mice is ameliorated by N-acetylcysteine but not D1 and D2 dopamine receptor agonists. Neuropsychopharmacology 2007, 32:531-541.
3. Acikgoz O., Gonenc S., Kayatekin B.M., Pekcetin C., Uysal N., Dayi A., Semin I., Gure A. The effects of single dose of methamphetamine on lipid peroxidation levels in the rat striatum and prefrontal cortex. Eur. Neuropsychopharmacol. 2000, 10:415-418.
4. Adams W., Ayton S., van den Buuse M. Serotonergic lesions of the dorsal hippocampus differentially modulate locomotor hyperactivity induced by drugs of abuse in rats: implications for schizophrenia. Psychopharmacology 2009, 206:665-676.
5. Agarwal R., Shukla G.S. Potential role of cerebral glutathione in the maintenance of blood-brain barrier integrity in rat. Neurochem. Res. 1999, 24:1507-1514.
6. Anand A., Verhoeff P., Seneca N., Zoghbi S.S., Seibyl J.P., Charney D.S., Innis R.B. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am. J. Psychiatry 2000, 157:1108-1114.
7. Aoyama K., Suh S.W., Hamby A.M., Liu J., Chan W.Y., Chen Y., Swanson R.A. Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat. Neurosci. 2006, 9:119-126.
8. Baker M.A., Cerniglia G.J., Zaman A. Microtiter plate assay for the measurement of glutathione and glutathione disulfide in large numbers of biological samples. Anal. Biochem. 1990, 190:360-365.
9. Beamish P., Kiloh L.G. Psychoses due to amphetamine consumption. J. Ment. Sci. 1960, 106:337-343.
10. Berk M., Ng F., Dean O., Dodd S., Bush A.I. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol. Sci. 2008, 29:346-351.
11. Berk M., Copolov D.L., Dean O., Lu K., Jeavons S., Schapkaitz I., Anderson-Hunt M., Bush A.I. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol. Psychiatry 2008, 64:468-475.
12. Berk M., Copolov D., Dean O., Lu K., Jeavons S., Schapkaitz I., Anderson-Hunt M., Judd F., Katz F., Katz P., Ording-Jespersen S., Little J., Conus P., Cuenod M., Do K.Q., Bush A.I. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol. Psychiatry 2008, 64:361-368.
13. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., Yucel M., Gama C.S., Dodd S., Dean B., Magalhaes P.V., Amminger P., McGorry P., Malhi G.S. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 2011, 35:804-817.
14. Borgstrom L., Kagedal B. Dose dependent pahrmacokinetics of n-acetylcysteine after oral doing to man. Biopharm. Drug Dispos. 1990, 11:131-136.
15. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2569-2574.
16. Carvalho F., Fernandes E., Remiao F., Gomes-Da-Silva J., Tavares M.A., Bastos M.D. Adaptative response of antioxidant enzymes in different areas of rat brain after repeated d-amphetamine administration. Addict. Biol. 2001, 6:213-221.
17. Chakraborti A., Gulati K., Banerjee B.D., Ray A. Possible involvement of free radicals in the differential neurobehavioral responses to stress in male and female rats. Behav. Brain Res. 2007, 179:321-325.
18. Chang T.T., Yeh T.L., Chiu N.T., Chen P.S., Huang H.Y., Yang Y.K., Lee I.H., Lu R.B. Higher striatal dopamine transporters in euthymic patients with bipolar disorder: a SPECT study with [Tc] TRODAT-1. Bipolar Disord. 2010, 12:102-106.
19. Choy K.H., Dean O., Berk M., Bush A.I., van den Buuse M. Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats. Eur. J. Pharmacol. 2010, 649:224-228.
20. Dean O., Bush A.I., Berk M., Copolov D.L., van den Buuse M. Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice. Behav. Brain Res. 2009, 198:258-262.
21. Dean O., Bush A.I., Berk M., Copolov D.L., van den Buuse M. Interaction of glutathione depletion and psychotropic drug treatment in prepulse inhibition in rats and mice. Pharmacol. Biochem. Behav. 2010, 97:293-300.
22. Dean O., Giorlando F., Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J. Psychiatry Neurosci. 2011, 36:78-86.
23. Do K.Q., Trabensinger M.K., Lauer C.J., Dydak U., Hell D., Holsboer F., Boesiger P., Cuenod K. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur. J. Neurosci. 2000, 12:3721-3728.
24. Dringen R., Pfeiffer B., Hamprecht B. Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of cysgly as precursor for neuronal glutathione. J. Neurosci. 1999, 19:562-569.
25. Dringen R., Gutterer J.M., Hirrlinger J. Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Eur. J. Biochem. 2000, 267:4912-4916.
26. Frey B.N., Martins M.R., Petronilho F.C., Dal-Pizzol F., Quevedo J., Kapczinski F. Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disord. 2006, 8:275-280.
27. Frey B.N., Valvassori S.S., Reus G.Z., Martins M.R., Petronilho F.C., Bardini K., Dal-Pizzol F., Kapczinski F., Quevedo J. Changes in antioxidant defense enzymes after d-amphetamine exposure: implications as an animal model of mania. Neurochem. Res. 2006, 31:699-703.
28. Fullerton J.M., Tiwari Y., Agahi G., Heath A., Berk M., Mitchell P.B., Schofield P.R. Assessing oxidative pathway genes as risk factors for bipolar disorder. Bipolar Disord. 2010, 12:550-556.
29. Gawryluk J.W., Wang J.F., Andreazza A.C., Shao L., Young L.T. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int. J. Neuropsychopharmacol. 2010, 1-8.
30. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl.) 2001, 156:117-154.
31. Grima G., Benz B., Parpura V., Cuenod M., Do K.Q. Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophr. Res. 2003, 62:213-224.
32. Harvey B.H., Joubert C., du Preez J.L., Berk M. Effect of chronic N-acetyl cysteine administration on oxidative status in the presence and absence of induced oxidative stress in rat striatum. Neurochem. Res. 2008, 33:508-517.
33. Holdiness M.R. Clinical pharmacokinetics of N-acetylcysteine. Clin. Pharmacokinet. 1991, 20:123-134.
34. Jacobs D., Silverstone T. Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol. Med. 1986, 16:323-329.
35. Khan M., Sekhon B., Jatana M., Giri S., Gilg A.G., Sekhon C., Singh I., Singh A.K. Administration of N-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke. J. Neurosci. Res. 2004, 76:519-527.
36. Laruelle M., Abi-Dargham A., Gil R., Kegeles L., Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol. Psychiatry 1999, 46:56-72.
37. Lavoie S., Murray M.M., Deppen P., Knyazeva M.G., Berk M., Boulat O., Bovet P., Bush A.I., Conus P., Copolov D., Fornari E., Meuli R., Solida A., Vianin P., Cuenod M., Buclin T., Do K.Q. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008, 33:2187-2199.
38. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K., Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry 2001, 50:884-897.
39. Lin H.C., Kang B.H., Wong C.S., Mao S.P., Wan F.J. Systemic administration of d-amphetamine induced a delayed production of nitric oxide in the striatum of rats. Neurosci. Lett. 1999, 276:141-144.
40. Meyer-Lindenberg A., Miletich R.S., Kohn P.D., Esposito G., Carson R.E., Quarantelli M., Weinberger D.R., Berman K.F. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci. 2002, 5:267-271.
41. Miller D.W., Abercrombie E.D. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res. Bull. 1996, 40:57-62.
42. Ng F., Berk M., Dean O., Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 2008, 11:851-876.
43. Sharp T., Zetterstrom T., Ljungberg T., Ungerstedt U. A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. Brain Res. 1987, 401:322-330.
44. Suhara T., Nakayama K., Inoue O., Fukuda H., Shimizu M., Mori A., Tateno Y. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology 1992, 106:14-18.
45. Tosic M., Ott J., Barral S., Bovet P., Deppen P., Gheorghita F., Matthey M.L., Parnas J., Preisig M., Saraga M., Solida A., Timm S., Wang A.G., Werge T., Cuenod M., Do K.Q. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am. J. Hum. Genet. 2006, 79:586-592.
46. van den Buuse M., Garner B., Gogos A., Kusljic S. Importance of animal models in schizophrenia research. Aust. N. Z. J. Psychiatry 2005, 39:550-557.
47. Vollenweider F.X., Maguire R.P., Leenders K.L., Mathys K., Angst J. Effects of high amphetamine dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET). Psychiatry Res. 1998, 83:149-162.
48. Yao J.K., Leonard S., Reddy R. Altered glutathione redox state in schizophrenia. Dis. Markers 2006, 22:83-93.